Teva announced Monday that it had introduced its generic version of Focalin XR (dexmethylphenidate hydrochloride) extended-release capsules in a new 20-mg dosage strength.
The move gives Teva standing in Dutch court, should they decide to pursue action against Mylan.
Teva and Microchips Biotech have announced a partnership that would test Microchips implantable drug delivery device with Teva’s portfolio.
Rite Aid's latest pharmacy initiative improves patient convenience and medication adherence.
The Daytona Beach News-Journal published a joint op-ed by Florida Retail Federation president and CEO Rick McAllister and National Association of Chain Drug Stores president and CEO Steve Anderson.
Aurobindo’s generic equivalent of anti-epileptic drug Dilantin has been approved by the Food and Drug Administration.
To talk about the challenges and opportunities facing community pharmacy, Drug Store News will host a special webinar on June 23, presented by Health Market Science, a LexisNexis company.
Drug Store News spoke to Doyle Jensen, Innovation’s EVP, global business development, about the technology solutions available to help pharmacists spend more time delivering patient-facing care.
The FDA has introduced a new website for Risk Evaluation and Mitigation Strategies, called REMS@FDA, to provide a standardized source of information about approved REMS.
Mylan’s largest shareholder has promised to back the company’s bid to buy Perrigo, which would help fend off Teva’s $40 billion takeover offer.